The following represents disclosure information provided by authors of this abstract. The Breast Cancer Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final results of NKTR-102, a topoisomerase I inhibitor-polymer conjugate, in patients (Pts) with pretreated metastatic breast cancer (MBC) demonstrating significant antitumor activity.
A. Garcia
Disclosure not yet available
A. Awada
Disclosure not yet available
S. Chan
Disclosure not yet available
G. H. M. Jerusalem
Disclosure not yet available
R. E. Coleman
Disclosure not yet available
M. T. Huizing
Disclosure not yet available
A. Mehdi
Disclosure not yet available
S. M. O'Reilly
Disclosure not yet available
J. T. Hamm
Disclosure not yet available
P. J. Barrett-Lee
Disclosure not yet available
V. Cocquyt
Disclosure not yet available
K. Sideras
Disclosure not yet available
D. E. Young
Disclosure not yet available
M. Brown
Disclosure not yet available
C. Zhao
Disclosure not yet available
A. L. Hannah
Disclosure not yet available
A. C. F. Leung
Disclosure not yet available
L. K. Masuoka
Disclosure not yet available
E. A. Perez
Disclosure not yet available